Benjamin Sy, MD
Pulmonary Disease · Bremerton, WANPI 1427075183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,350 of the $93,036 with a category attached, or 92.8%. AstraZeneca accounts for 99.8% of it on its own, with 3 other manufacturers making up the rest. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $809.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$93K
- Bayer$125
- Insmed, Inc.$19
- Boehringer Ingelheim$13
What the payments were for
- Consulting fees$1250%
- Speaking & faculty fees$86,35093%
- Travel & lodging$4,3985%
- Food & beverage$2,1642%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 112 | $92,879 |
| Bayer | 1 | $125 |
| Insmed, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,036 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 20 | $274,181 |
| Spiriva RespimatTiotropium Bromide | 293 | $218,636 |
| AdempasRiociguat | 13 | $183,140 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 203 | $129,208 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $69,013 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $65,397 |
| Advair HfaFluticasone Propion/Salmeterol | 116 | $62,388 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $61,536 |
| Ambrisentan | 27 | $58,537 |
| Spiriva HandihalerTiotropium Bromide | 41 | $55,719 |
| TezspireTezepelumab-Ekko | 12 | $54,200 |
| Incruse ElliptaUmeclidinium Bromide | 89 | $45,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $44,460 |
| SymbicortBudesonide/Formoterol Fumarate | 128 | $44,195 |
| DuleraMometasone/Formoterol | 90 | $37,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $13 | $347,844496 claims |
| BayerAdempas | $125 | $183,14013 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Pulmicort Flexhaler | $92,879 | $169,816255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Bremerton
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
- Colleen OverdorfBellingham$110K
- Jeffrey CarySeattle$106K
- Richard RedmanOlympia$86K
- Amy DickeySeattle$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.